GlassScriptPhysician profile
Roberto A Ferro Valdes
NPI 1861780108
$142,099.03
in general payments reported to CMS, 2019-2025
64 companies · $862 in 2025
The $862 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $27K · 2021: $15K · 2022: $32K · 2023: $7,283 · 2024: $4,575 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,925 · Food and Beverage: $2,747 · Travel and Lodging: $48.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,925.00 |
| Food and Beverage | $2,746.93 |
| Travel and Lodging | $48.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $75,829.34 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Astellas Pharma US INC | $20,300.02 | 2019-2025 | Xospata, Vyloy |
| Abbvie INC. | $12,174.55 | 2019-2024 | |
| Kite Pharma, INC. | $7,291.81 | 2019-2025 | Yescarta |
| Glaxosmithkline, LLC. | $4,530.49 | 2020-2025 | Ojjaara |
| Genentech, INC. | $3,672.26 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $3,423.30 | 2019-2025 | Opdivo |
| Genzyme Corporation | $2,888.41 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,159.45 | 2019-2025 | |
| Dova Pharmaceuticals | $1,800.26 | 2019-2020 | |
| Seagen INC. | $1,584.70 | 2019-2023 | Padcev |
| Celgene Corporation | $1,432.11 | 2020-2024 | Reblozyl |
| Epizyme, INC. | $1,250.00 | 2021 | |
| Genentech USA, INC. | $435.78 | 2019-2024 | Polivy, Lunsumio, Gazyva |
| Incyte Corporation | $273.63 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 63 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Ferro Valdes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.